How much revenue did Organo generate this year?
Organo has achieved a revenue of 150.36 B JPY this year.
Organo Revenue 2024
Organo Revenue
150.36 B JPY
Ticker
6368.T
ISIN
JP3201600008
In 2024, Organo's sales reached 150.36 B JPY, a 13.54% difference from the 132.43 B JPY sales recorded in the previous year.
The Organo Revenue history
| YEAR | REVENUE (undefined JPY) | GROSS MARGIN (%) |
|---|---|---|
| 2027e | 183.96 | 23,83 |
| 2026e | 172.79 | 25,37 |
| 2025e | 161.15 | 27,21 |
| 2024 | 150.36 | 29,16 |
| 2023 | 132.43 | 26,41 |
| 2022 | 112.07 | 25,44 |
| 2021 | 100.64 | 26,16 |
| 2020 | 96.52 | 28,27 |
| 2019 | 92.27 | 24,84 |
| 2018 | 79.23 | 24,17 |
| 2017 | 81.11 | 22,98 |
| 2016 | 78.72 | 22,55 |
| 2015 | 68.74 | 22,61 |
| 2014 | 62.1 | 23,44 |
| 2013 | 66.72 | 25,25 |
| 2012 | 68.5 | 26,81 |
| 2011 | 61.1 | 26,14 |
| 2010 | 53.52 | 26,02 |
| 2009 | 73.12 | 23,18 |
| 2008 | 73.59 | 24,51 |
| 2007 | 78.47 | 27,63 |
| 2006 | 75.7 | 24,64 |
| 2005 | 77.61 | 22,26 |
Organo Revenue, EBIT, Net Income JP3201600008 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Organo, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Organo from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Organo’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Organo. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Organo’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Organo’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Organo’s growth potential.
Organo Revenue, EBIT and net profit per share
| Date | Organo Revenue | Organo EBIT | Organo Net Income |
|---|---|---|---|
| 2027e | 183.96 B undefined | 0 undefined | 22.29 B undefined |
| 2026e | 172.79 B undefined | 0 undefined | 20.13 B undefined |
| 2025e | 161.15 B undefined | 0 undefined | 18.23 B undefined |
| 2024 | 150.36 B undefined | 22.54 B undefined | 17.31 B undefined |
| 2023 | 132.43 B undefined | 15.21 B undefined | 11.73 B undefined |
| 2022 | 112.07 B undefined | 10.85 B undefined | 9.21 B undefined |
| 2021 | 100.64 B undefined | 9.58 B undefined | 7.07 B undefined |
| 2020 | 96.52 B undefined | 9.91 B undefined | 7.16 B undefined |
| 2019 | 92.27 B undefined | 6.56 B undefined | 4.45 B undefined |
| 2018 | 79.23 B undefined | 3.82 B undefined | 2.78 B undefined |
| 2017 | 81.11 B undefined | 4.11 B undefined | 2.73 B undefined |
| 2016 | 78.72 B undefined | 3.95 B undefined | 2.49 B undefined |
| 2015 | 68.74 B undefined | 2.4 B undefined | 1.09 B undefined |
| 2014 | 62.1 B undefined | 833 M undefined | 664 M undefined |
| 2013 | 66.72 B undefined | 3.5 B undefined | 2.56 B undefined |
| 2012 | 68.5 B undefined | 4.85 B undefined | 2.68 B undefined |
| 2011 | 61.1 B undefined | 3.53 B undefined | 1.86 B undefined |
| 2010 | 53.52 B undefined | 1.85 B undefined | 646 M undefined |
| 2009 | 73.12 B undefined | 3.06 B undefined | 1.62 B undefined |
| 2008 | 73.59 B undefined | 3.85 B undefined | 2.46 B undefined |
| 2007 | 78.47 B undefined | 7.52 B undefined | 4.48 B undefined |
| 2006 | 75.7 B undefined | 4.25 B undefined | 2.01 B undefined |
| 2005 | 77.61 B undefined | 3.03 B undefined | 1.74 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 77.61 B JPY | 3.03 B JPY | 1.74 B JPY |
| 2006 | 75.7 B JPY | 4.25 B JPY | 2.01 B JPY |
| 2007 | 78.47 B JPY | 7.52 B JPY | 4.48 B JPY |
| 2008 | 73.59 B JPY | 3.85 B JPY | 2.46 B JPY |
| 2009 | 73.12 B JPY | 3.06 B JPY | 1.62 B JPY |
| 2010 | 53.52 B JPY | 1.85 B JPY | 646 M JPY |
| 2011 | 61.1 B JPY | 3.53 B JPY | 1.86 B JPY |
| 2012 | 68.5 B JPY | 4.85 B JPY | 2.68 B JPY |
| 2013 | 66.72 B JPY | 3.5 B JPY | 2.56 B JPY |
| 2014 | 62.1 B JPY | 833 M JPY | 664 M JPY |
| 2015 | 68.74 B JPY | 2.4 B JPY | 1.09 B JPY |
| 2016 | 78.72 B JPY | 3.95 B JPY | 2.49 B JPY |
| 2017 | 81.11 B JPY | 4.11 B JPY | 2.73 B JPY |
| 2018 | 79.23 B JPY | 3.82 B JPY | 2.78 B JPY |
| 2019 | 92.27 B JPY | 6.56 B JPY | 4.45 B JPY |
| 2020 | 96.52 B JPY | 9.91 B JPY | 7.16 B JPY |
| 2021 | 100.64 B JPY | 9.58 B JPY | 7.07 B JPY |
| 2022 | 112.07 B JPY | 10.85 B JPY | 9.21 B JPY |
| 2023 | 132.43 B JPY | 15.21 B JPY | 11.73 B JPY |
| 2024 | 150.36 B JPY | 22.54 B JPY | 17.31 B JPY |
| 2025e | 161.15 B JPY | 0 JPY | 18.23 B JPY |
| 2026e | 172.79 B JPY | 0 JPY | 20.13 B JPY |
| 2027e | 183.96 B JPY | 0 JPY | 22.29 B JPY |
Organo stock margins JP3201600008 ·
The Organo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Organo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Organo.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Organo's sales revenue. A higher gross margin percentage indicates that the Organo retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Organo's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Organo's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Organo's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Organo. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Organo's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Organo Margin History
| Organo Gross margin | Organo Profit margin | Organo EBIT margin | Organo Profit margin |
|---|---|---|---|
| 2027e | 29.16 % | 0 % | 12.12 % |
| 2026e | 29.16 % | 0 % | 11.65 % |
| 2025e | 29.16 % | 0 % | 11.31 % |
| 2024 | 29.16 % | 14.99 % | 11.51 % |
| 2023 | 26.41 % | 11.49 % | 8.86 % |
| 2022 | 25.44 % | 9.68 % | 8.22 % |
| 2021 | 26.16 % | 9.52 % | 7.03 % |
| 2020 | 28.27 % | 10.27 % | 7.42 % |
| 2019 | 24.84 % | 7.11 % | 4.82 % |
| 2018 | 24.17 % | 4.82 % | 3.51 % |
| 2017 | 22.98 % | 5.07 % | 3.37 % |
| 2016 | 22.55 % | 5.01 % | 3.16 % |
| 2015 | 22.61 % | 3.49 % | 1.58 % |
| 2014 | 23.44 % | 1.34 % | 1.07 % |
| 2013 | 25.25 % | 5.24 % | 3.84 % |
| 2012 | 26.81 % | 7.08 % | 3.92 % |
| 2011 | 26.14 % | 5.78 % | 3.04 % |
| 2010 | 26.02 % | 3.45 % | 1.21 % |
| 2009 | 23.18 % | 4.19 % | 2.21 % |
| 2008 | 24.51 % | 5.24 % | 3.34 % |
| 2007 | 27.63 % | 9.59 % | 5.7 % |
| 2006 | 24.64 % | 5.61 % | 2.66 % |
| 2005 | 22.26 % | 3.9 % | 2.24 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 22.26 % | 3.9 % | 2.24 % |
| 2006 | 24.64 % | 5.61 % | 2.66 % |
| 2007 | 27.63 % | 9.59 % | 5.7 % |
| 2008 | 24.51 % | 5.24 % | 3.34 % |
| 2009 | 23.18 % | 4.19 % | 2.21 % |
| 2010 | 26.02 % | 3.45 % | 1.21 % |
| 2011 | 26.14 % | 5.78 % | 3.04 % |
| 2012 | 26.81 % | 7.08 % | 3.92 % |
| 2013 | 25.25 % | 5.24 % | 3.84 % |
| 2014 | 23.44 % | 1.34 % | 1.07 % |
| 2015 | 22.61 % | 3.49 % | 1.58 % |
| 2016 | 22.55 % | 5.01 % | 3.16 % |
| 2017 | 22.98 % | 5.07 % | 3.37 % |
| 2018 | 24.17 % | 4.82 % | 3.51 % |
| 2019 | 24.84 % | 7.11 % | 4.82 % |
| 2020 | 28.27 % | 10.27 % | 7.42 % |
| 2021 | 26.16 % | 9.52 % | 7.03 % |
| 2022 | 25.44 % | 9.68 % | 8.22 % |
| 2023 | 26.41 % | 11.49 % | 8.86 % |
| 2024 | 29.16 % | 14.99 % | 11.51 % |
| 2025e | 29.16 % | 0 % | 11.31 % |
| 2026e | 29.16 % | 0 % | 11.65 % |
| 2027e | 29.16 % | 0 % | 12.12 % |
Organo Aktienanalyse
What does Organo do?
Organo Corp is an internationally operating company specialized in the production and distribution of products in the health and wellness industry. The company was founded in Vancouver, Canada in 2008 by Bernardo Chua. Organo Corp's business model is based on network marketing to sell its products. This has allowed the company to quickly build a large customer base and become active in over 50 countries. The goal of Organo Corp is to help every customer lead a healthier and happier life. Organo Corp is divided into different divisions to offer customers a wide range of products. One of the main divisions is "Organo Gold," which offers coffee and tea products. These products are based on traditional Asian herbs and fungi such as Reishi, Ganoderma, and Cordyceps. These herbs have many active ingredients that strengthen the immune system, increase energy levels, reduce stress, and promote overall well-being. Another division of Organo Corp is "Organo Essentials," which offers products for a healthy everyday life. This includes supplements such as multivitamin tablets, protein powder, and Omega-3 fatty acids. These supplements are made from high-quality ingredients and aim to improve overall well-being. Organo Corp also has a "Personal Care" division, which offers products for personal hygiene. These include soaps, shampoos, creams, and lotions. These products contain natural ingredients such as tea tree oil, aloe vera, shea butter, and various essential oils that are intended to nourish and protect the skin. The company also has an "Organo Graphics" division, which offers marketing materials to help independent distributors of Organo Corp build their own business. This includes brochures, business cards, and sales tools. Organo Corp has also made a name for itself through various philanthropic activities. The company has established the "OG Care Foundation," which advocates for disadvantaged children and their families worldwide. The foundation supports projects in the areas of education, health, and well-being. In summary, Organo Corp is a company specializing in the sale of products in the health and wellness industry. The company offers a wide range of products based on natural ingredients such as Asian herbs and fungi. Through network marketing, Organo Corp has quickly built a large customer base and is now active in over 50 countries. Additionally, the company is committed to supporting disadvantaged children around the world through the "OG Care Foundation." Organo ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Organo's Sales Figures
The sales figures of Organo originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Organo’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Organo's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Organo’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Organo stock
How much was the turnover of the company Organo compared to the previous year?
The revenue of Organo has increased by 13.54% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Organo?
The revenue of Organo is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Organo measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Organo so important for investors?
The revenue of Organo is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Organo pay?
Over the past 12 months, Organo paid a dividend of 114 JPY . This corresponds to a dividend yield of about 1.85 %. For the coming 12 months, Organo is expected to pay a dividend of 118.51 JPY.
What is the dividend yield of Organo?
The current dividend yield of Organo is 1.85 %.
When does Organo pay dividends?
Organo pays a quarterly dividend. This is distributed in the months of October, April, October, April.
How secure is the dividend of Organo?
Organo paid dividends every year for the past 23 years.
What is the dividend of Organo?
For the upcoming 12 months, dividends amounting to 118.51 JPY are expected. This corresponds to a dividend yield of 1.92 %.
In which sector is Organo located?
Organo is assigned to the 'Industry' sector.
Wann musste ich die Aktien von Organo kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Organo from 12/1/2024 amounting to 53 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.
When did Organo pay the last dividend?
The last dividend was paid out on 12/1/2024.
What was the dividend of Organo in the year 2023?
In the year 2023, Organo distributed 74 JPY as dividends.
In which currency does Organo pay out the dividend?
The dividends of Organo are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Organo
Our stock analysis for Organo Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Organo Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
